Kymera Therapeutics, Inc. Common Stock

KYMRNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
74.13 USD
↘ 0.48 (0.64%)AT CLOSE (11:59 AM EDT)
74.16
↗ 0.03 (0.03%)
POST MARKET (AS OF 07:13 PM EDT)
Post Market
AS OF 07:13 PM EDT
74.16
↗ 0.03 (0.03%)
🔴Market: CLOSED
Open?$74.36
High?$75.39
Low?$72.77
Prev. Close?$74.61
Volume?639.5K
Avg. Volume?530.0K
VWAP?$74.41
Rel. Volume?1.21x
Bid / Ask
Bid?$63.79 × 100
Ask?$84.88 × 100
Spread?$21.09
Midpoint?$74.34
Valuation & Ratios
Market Cap?6.1B
Shares Out?82.3M
Float?24.2M
Float %?77.2%
P/E Ratio?N/A
P/B Ratio?3.99
EPS?-$3.83
Dividend?0.00%
Ex-Dividend?N/A

KYMR is currently priced at $74.12. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, KYMR is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
253
Market Cap
6.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.kymeratx.com
Listed
2020-08-21
Address
500 NORTH BEACON STREET, 4TH FLOOR
WATERTOWN, MA 02472
Phone: 857-285-5314
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
23
Short Sent.?
10
Piotroski F-Score?4/9Mixed
Altman Z-Score?27.27Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?41.32%Squeeze Risk
Short Interest?10.0M
Days to Cover?21.3
Free Float24.2M
Avg Daily Volume469.9K
Settlement Date2026-05-15
Financial Health
Current Ratio?10.81Strong
Quick Ratio?10.81Strong
Cash Ratio?2.30Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
45
3.99FAIR▾
P/S?
Peers
100
S&P
3
119.23HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-17.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
116.48HIGH▾
Returns & Efficiency
ROE?
S&P
8
-20.5%WEAK▾
ROA?
S&P
3
-18.9%WEAK▾
Cash Flow & Enterprise
FCF?$-243997000
Enterprise Value?$6.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist